Concord Biotech clarifies on trading volume spike

Concord Biotech responds to BSE inquiry about increased trading volume, confirming compliance with disclosure norms and stating no undisclosed price-sensitive information pending announcement.

Concord Biotech Company Secretary Resigns

Hina Patel, Company Secretary and Compliance Officer at Concord Biotech Limited, has tendered her resignation to pursue opportunities outside the organization, effective January 21, 2026.

Concord Biotech CFO Lalit Sethi Announces Early Retirement Due to Personal Reasons

Concord Biotech Limited's Chief Financial Officer Mr. Lalit Sethi has submitted his intention to retire early due to personal reasons including family commitments and health considerations as he approaches age 59, effective close of business hours on January 5, 2026. The company has closed its trading window from December 8, 2025 for 48 hours following the announcement, with Sethi committing to ensure seamless transition of financial statements, compliance documentation, and investor relations materials.

Concord Biotech Reports 20% Revenue Decline in Q2 FY26 Due to Regulatory Delays and Market Disruptions

Concord Biotech's Q2 FY26 revenues dropped to Rs. 247 crores from Rs. 310 crores year-on-year, primarily due to CDSCO written confirmation delays affecting EU sales, deferred Middle East government tender, and US procurement pattern shifts from tariff uncertainties. The company expects stronger H2 performance as regulatory approvals are now received and delayed shipments resume, with EBITDA margins at 41% excluding injectable facility startup costs.